Fig. 6

Tyrosine kinase inhibitors demonstrate significant potential in UTUC treatment. A Both CTRPv2 and Prism share 204 common drugs. B Risk scores for all cell lines in the CCL database, urothelial cell lines, and metastatic urothelial cell lines. C Drug screening methodology for CTRPv2 and Prism. D Results of shared expression analysis (r < -0.2, Spearman correlation) between selected drugs from CTRPv2 and risk scores. E Normalized AUC values for drugs selected by CTRPv2 in high-risk and low-risk groups. F Results of shared expression analysis (Spearman correlation, r < -0.2) between selected drugs from Prism and risk scores. G Normalized AUC values for drugs selected by Prism in high-risk and low-risk groups. H Validation of drug selection results from CTRPv2 and Prism in the CMap database, to identify more potential drugs for targeted UTUC treatment. I, J Identification of kidney fibrosis in the Aristolochic acid induced kidney disease mouse model using Masson's trichrome staining in the Erlotinib and saline groups. K Potential mode of action for tyrosine kinase inhibitors. (p ≤ 0.05 as *, p ≤ 0.01 as **, p ≤ 0.001 as ***, p ≤ 0.0001 as ****)